ENB is developing platform oncology molecules to unlock the full therapeutic potential of immune-based cancer therapies

ETBR Blockers

Our target, the endothelin B receptor (ETBR), has been linked to melanoma and other cancers in over 200 peer-reviewed publications. It causes uncontrolled cancer growth, drives cancers to spread through the body, and prevents the immune system from detecting and killing cancer cells. However, no drug specifically blocking the ETBR has ever been brought to market or even tested in clinical trials for cancer. Drugs that blocked other receptors in the same family failed in clinical trials for cancer because, unlike our therapies, they actually prevent the immune system from killing cancer cells.

Our lead product ENB-003 specifically blocks the ETBR and is proven to help otherwise ineffective immunotherapies kill cancer cells. ENB-003 has an established safety profile in humans and, unlike approved drugs on the market that kill many normal cells in the body, it is anticipated to stimulate the immune system to only target and kill cancer cells.

Our products, as combination therapy with immuno-oncology agents, create a new and superior standard of care that blocks key mechanisms of drug resistance, stimulates the immune system to fight cancer, and prevents cancer from spreading.

We have the key to unlock the full therapeutic potential
of immuno-oncology platforms.

Our team

Sumayah Jamal, MD, PhD

President, Co-founder, Chief Scientific Officer

Sumayah Jamal
  • Research career spanning 30+ years
  • Co-inventor on first patents filed covering the endothelin B receptor as a therapeutic target of cancer
  • Work conducted as a Principal Investigator at NYU School of Medicine serves as the foundation for the drug development programs of ENB Therapeutics
  • The American Academy of Dermatology Young Investigator Award
  • The American Academy of Dermatology Everett C. Fox M.D. Award
  • The Pan American Society for Pigment Cell Research Young Investigator Award

Sandy Harm

Chief Operating Officer

Sandy Harm
  • 24 years as a senior executive at Merck
  • Pharmaceutical and healthcare leader with extensive experience in Research and Development Operations from bench to commercialization
  • Strong background in clinical research, Investigator-Initiated Studies, customer interactions, project management, launch planning, medical affairs strategy, operations and planning, and compliant business practices and sales
  • Broad-based disease area experience, with particular expertise in oncology (10+ years), and 15+ years of customer interactions
  • Oversaw launch and development of Keytruda

Robert Schneider, PhD

Co-founder, Chair of Scientific Advisory Board

Robert Schneider
  • Associate Director for Translational Research, NYU Cancer Institute, Director, Breast Cancer Program, Albert Sabin Professor of Molecular Pathogenesis
  • Senior Principal Investigator, oversees Drug Discovery and Development programs at NYUMC
  • Strong track record of licensing inventions and intellectual property to industry and investment partners
  • Co-founder of numerous successful biopharma start-up companies including ImClone, Canji, and PTC Therapeutics

Preview Our Investor Deck

Get in touch